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Abstract
Background:  Aggregatibacter actinomycetemcomitans is an oral bacterium associated with
aggressively progressing periodontitis. Extracellular release of bacterial outer membrane proteins
has been suggested to mainly occur via outer membrane vesicles. This study investigated the
presence and conservation of peptidoglycan-associated lipoprotein (AaPAL) among A.
actinomycetemcomitans strains, the immunostimulatory effect of AaPAL, and whether live cells
release this structural outer membrane lipoprotein in free-soluble form independent of vesicles.
Results: The pal locus and its gene product were confirmed in clinical A. actinomycetemcomitans
strains by PCR-restriction fragment length polymorphism and immunoblotting. Culturing under
different growth conditions revealed no apparent requirement for the AaPAL expression.
Inactivation of pal in a wild-type strain (D7S) and in its spontaneous laboratory variant (D7SS)
resulted in pleiotropic cellular effects. In a cell culture insert model (filter pore size 0.02 µm),
AaPAL was detected from filtrates when strains D7S and D7SS were incubated in serum or broth
in the inserts. Electron microscopy showed that A. actinomycetemcomitans vesicles (0.05–0.2 µm)
were larger than the filter pores and that there were no vesicles in the filtrates. The filtrates were
immunoblot negative for a cytoplasmic marker, cyclic AMP (cAMP) receptor protein. An ex vivo
model indicated cytokine production from human whole blood stimulated by AaPAL.
Conclusion: Free-soluble AaPAL can be extracellularly released in a process independent of
vesicles.
Background
Aggregatibacter actinomycetemcomitans [1] is a small Gram-
negative rod implicated in aggressive forms of periodonti-
tis [2]. We recently identified and characterized in A. actin-
omycetemcomitans  a 17-kDa peptidoglycan-associated
lipoprotein (PAL) [3,4], which is a widely conserved outer
membrane lipoprotein (OMLP) among Gram-negative
bacteria [5]. The PALs of several pathogens, such as Hae-
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mophilus influenzae, Escherichia coli [6-9], Legionella pneu-
mophila, Bordetella pertussis, and Campylobacter jejuni [10-
12] are proinflammatory and/or strongly immunogenic
and can contribute to serum resistance of the bacterium
[13]. PAL may be an important bacterial mediator in sep-
sis caused by Gram-negative bacteria [7] and is crucial for
full expression of virulence of Haemophilus ducreyi [14].
Extracellular release of bacterial virulence factors is a prin-
cipal mechanism of bacterial pathogenicity [15]. Different
strategies of release include specialized secretory systems
[15-17], outer membrane vesicles [18,19], and autolysis
[20]. Release of outer membrane vesicles is regarded as the
primary mechanism for delivering structural surface com-
ponents, such as outer membrane proteins (OMP) and
lipopolysaccharide (LPS), into the extracellular milieu.
Most previous studies on the released bacterial outer
membrane components, however, have focused on
detecting and isolating them from serum or culture super-
natants, or on testing their biological activity [21-25]. Less
attention has been directed to elucidating whether these
components in the test material were derived from lysed
cells, outer membrane vesicles, and/or were released from
live bacteria in free-soluble form. Importantly, the bacte-
rial cell components that are released in free-soluble form
may be biologically more active than their membrane-
bound counterparts associated with intact bacterial cells
or outer membrane vesicles [26].
The present study was designed to investigate the presence
and conservation of PAL among clinical A. actinomycetem-
comitans strains and whether live A. actinomycetemcomitans
cells release PAL (AaPAL) in free-soluble form. To accom-
plish these objectives, inserts with 0.02-µm pore-size filter
were used to separate bacterial cells from cell culture wells
containing serum or broth. We present compelling evi-
dence for the release of AaPAL in free-soluble form by
demonstrating presence of AaPAL in the filtrates obtained
after incubation, by monitoring bacterial viability in the
insert, and by checking for the absence of cell lysis and
outer membrane vesicles in the filtrate. Proinflammatory
effect of AaPAL was shown in an ex vivo model using
human whole blood.
Results
The pal gene was conserved and the protein expressed in 
clonally diverse A. actinomycetemcomitans strains
A total of 33 A. actinomycetemcomitans strains were ana-
lyzed by PCR and immunoblotting. The results from 12
strains representing 6 serotypes and 9 genotypes are
shown (Fig. 1). The genomic DNA and the whole cell pro-
tein preparation of these strains each produced the
expected 425-bp amplicon in PCR and the 17-kDa immu-
noblot signal with anti-AaPAL peptide antiserum, respec-
tively.
The RFLP analysis with two enzymes, DdeI and BspMI, cut-
ting once within the pal sequence [4] showed that the
restriction patterns were similar among all test strains
(Fig. 1). The DdeI-digested fragments were 175 and 250
bp, as predicted, whereas the BspMI-digested fragments
were 100 and 225 bp, which were not the predicted sizes
of 324 and 101 bp, respectively. The reason seems to be a
recognition site for BspMI on the opposite strand approx-
imately 100 bp away from the reverse primer binding
sequence.
AaPAL was expressed in various culture conditions
To determine the environmental requirements for AaPAL
expression, we cultured A. actinomycetemcomitans strains
in different nutritional and atmospheric conditions.
Besides conventional cultures, strains were also grown as
biofilm [27]. The immunoblot analyses of the whole cell
protein preparations of strains D7S and D7SS, but not
D7SS-p, revealed 17-kDa signals, regardless of the culture
conditions (Fig. 2). Furthermore, the 17-kDa band
appeared stronger when strains D7S and D7SS had been
grown in broth incubated in CO2-supplemented (5%) air
than when grown in other conditions. A particularly
PCR-RFLP of pal and detection of its gene product, PAL,  from clonally diverse A. actinomycetemcomitans strains Figure 1
PCR-RFLP of pal and detection of its gene product, PAL, 
from clonally diverse A. actinomycetemcomitans strains. Panel 
A: Agarose gel electrophoresis of the PCR products shows 
amplicons with the expected size of pal (425 bp) for each 
strain. Panels B and C: Agarose gel electrophoresis of the 
purified PCR amplicons digested with DdeI and BspMI, sepa-
rately. Panel D: immunoblot analysis of the A. actinomycetem-
comitans whole cell protein preparations using anti-AaPAL 
peptide antiserum shows the expected 17-kDa signal for 
each strain. Lanes 1 through 12 strain identification (sero-
type; genotype): ATCC 29523 (a; 1), SA5002 (a; 1), ATCC 
43718 (b; 2), SA5003 (b; 8), ATCC 33384 (c; 3), SA5005 (c; 
3), SA5001 (d; 5), SA5007 (d; 22), SA5008 (e; 6), SA5011 (e; 
20), CU1000R (f; nd*), SA5022 (f; 19) and standards (S). *nd: 
not determined.
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strong band was also seen for strain D7S grown as biofilm
under anaerobic incubation.
Phenotype of the pal-deficient mutants
The strain D7SS-p was constructed to be used as a negative
control in the experiments. The strain D7S-p was also con-
structed to serve as a negative control, but particularly in
the experiments aimed to demonstrate with a clinical
strain, D7S, that AaPAL release was not restricted to its
spontaneous laboratory variant, D7SS.
Comparison between the phenotypes of the mutants and
their parents (data for D7SS and D7SS-p are shown in Fig.
3) showed no distinct differences in the colony sizes or
densities when standardized numbers of cells (1 × 103)
were cultured on plates. The mutants, however, exhibited
filamentous cell morphology when observed by wet
mounting (phase contrast microscopy) and SEM. The
altered cell morphology was more pronounced when bac-
teria were cultured in nutritionally poor (TSA) rather than
in rich (supplemented blood agar) medium (data not
shown). As judged from the SEM analysis, there was
enhanced vesicle production by the strain D7SS-p relative
to D7SS (Fig. 3Ae and 3f). Furthermore, the growth rate of
the mutant appeared inferior to the parent (Fig. 3B). The
antibiotic susceptibility comparison between the strains
showed that for the mutant, the inhibition zone was
larger (P < 0.05) for erythromycin but not for cefotaxime
or penicillin (Fig. 3C).
AaPAL was detected in serum and broth filtrates
To elucidate how AaPAL could be presented to the host
during  A. actinomycetemcomitans infection, we studied
whether  A. actinomycetemcomitans cells released AaPAL
into extracellular space in free-soluble form. For this pur-
pose, we designed an in vitro model, where standardized
numbers of bacterial cells were exposed for up to 8 h to
heat-inactivated FCS (Fig. 4A). To explore the possibility
of AaPAL release during A. actinomycetemcomitans growth,
another similar experiment using D7SS and D7SS-p was
performed using culture broth and a longer incubation
time (24 h) (Fig. 4B). Immunoblot analysis of the filtrates
outside the inserts containing strain D7SS or D7S revealed
an accumulation of AaPAL over time (data for D7SS and
D7SS-p are shown in Fig. 4). No AaPAL was detected in
the above experiments at any time point in the filtrate
when either D7SS-p or D7S-p or No bacteria were incu-
bated in the insert. In all of the above described serum and
broth experiments, OMP preparations of strains D7SS and
D7SS-p were used as positive and negative controls,
respectively, in the immunoblot assays (data not shown).
Densitometric quantification indicated that for strain
D7SS incubated in serum, AaPAL concentration after the
first 2 h was 637 ng/ml and at 8 h was 932 ng/ml (a 1.5-
fold increase from 2 h). Similarly, for strain D7S incu-
bated in serum, AaPAL concentration after the first 2 h was
437 ng/ml and at 8 h was 750 ng/ml (a 1.7-fold increase
from 2 h). For strain D7SS in broth, AaPAL concentration
at 24 h was 194 ng/ml (for strain D7S, only serum incu-
bation was performed).
To ensure the viability of the bacteria during the AaPAL
release experiments described above, we employed bacte-
rial viable counts for samples taken from serum and broth
inside the inserts at the same time points as samples that
were taken from filtrates for the immunoblot analyses
(data for D7SS and D7SS-p are presented in Fig. 4C). In
serum, the mean CFU (per ml) counts of D7SS were 1.1-
fold higher at 2 h than at 0 h and 46.0-fold higher at 8 h
than at 2 h. Similarly, the mean CFU counts of D7SS-p
were 1.3-fold higher at 2 h than at 0 h and 30.0-fold
higher at 8 h than at 2 h.
In broth, the mean CFU counts of D7SS were 34.3-fold
higher at 24-h than at 0 h. In contrast, the CFU counts of
D7SS-p were 62.2-fold lower at 24 h than at 0 h (Fig. 4C).
Since the AaPAL release experiment was performed for
strains D7S and D7S-p in serum only, the viable count
data are given here: The mean CFU counts of D7S were at
0 h 6.2 × 108, at 2 h 8.7 × 108 (a 1.4-fold increase), and at
8 h 1.16 × 1010 (a 13.3-fold increase from 2 h). The respec-
tive mean CFU counts for D7S-p were at 0 h 6.1 × 108, at
AaPAL expression in different growth conditions of A. actino- mycetemcomitans Figure 2
AaPAL expression in different growth conditions of A. actino-
mycetemcomitans. Strains D7S (wild-type, lane 1), D7SS 
(spontaneous smooth-colony variant of D7S, lane 2), and 
D7SS-p (pal-deficient mutant of D7SS, lane 3) were cultured 
in various nutritional and atmospheric conditions (for details, 
see Materials and Methods). Bacterial whole cell protein 
preparations (10 µg/well) were subjected to immunoblot 
analysis with anti-AaPAL peptide antiserum. The OMP prepa-
rations from the strains D7SS (lane 4) and D7SS-p (lane 5) 
were used as a positive and a negative control, respectively. 
CO2: CO2-enriched air (5%); BA: blood agar; TSA: trypticase 
soy agar.
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Role of AaPAL in cell physiology and membrane integrity Figure 3
Role of AaPAL in cell physiology and membrane integrity. Panel A: Colony density and morphology (a, b) and the cell morphol-
ogy of A. actinomycetemcomitans strains D7SS and D7SS-p grown on TSA as examined by phase contrast microscopy (c, d) and 
scanning electron microscopy (e, f). Panel B: Growth rates of D7SS and D7SS-p in TSB measured by turbidimetry (OD600). The 
results are shown from two separate experiments. Panel C: Antibiotic susceptibility comparison between the strains D7SS and 
D7SS-p. The results are means (SD) from three independent experiments (*P < 0.05). P, penicillin; E, erythromycin; C, cefotax-
ime.
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2 h 9.5 × 108 (a 1.5-fold increase), and at 8 h 1.4 × 1010 (a
15.0-fold increase from 2 h).
No bacterial growth was found in the samples from the
serum or broth filtrates at any time point, ensuring that
bacteria growing within the inserts had not passed
through the filter and/or that the filtrates had not been
contaminated.
For D7SS incubated in serum, although the mean LPS
concentrations of the filtrates decreased 1.1-fold from 0 h
to 2 h, there was an increase of 1.7-fold from 2 h to 8 h.
The mean LPS concentrations for strain D7SS-p incubated
in serum increased 1.0-fold from 0 h to 2 h and 2.6-fold
from 2 h to 8 h (Fig. 5). During broth culture, the mean
LPS concentrations for D7SS and D7SS-p increased 2.5-
and 9.8-fold, respectively, from 0 h to 24 h. However,
there were no statistically significant differences in the
amounts of LPS in the serum or broth filtrates between the
two strains at any time point or in regard to the No bacte-
ria control between the different time points. At the 0 time
point, the LPS concentrations of D7SS and D7SS-p in
both serum and broth filtrates were almost equal to those
of the respective No bacteria control samples (Fig. 5).
We also tested for the release of additional A. actinomyce-
temcomitans components, apart from PAL and LPS, in the
filtrates. Immunoblot analysis of the filtrates after an 8-h
Immunoblot detection of PAL release from A. actinomycetemcomitans cells exposed to heat-inactivated FCS or cultured in broth Figure 4
Immunoblot detection of PAL release from A. actinomycetemcomitans cells exposed to heat-inactivated FCS or cultured in 
broth. The samples were obtained from cell-culture wells outside the inserts, where the bacteria [D7SS (lane 1) and D7SS-p 
(lane 2)] or No bacteria (lane 3) were incubated in serum for 2 h and 8 h (Panel A) or cultured in broth for 24 h (Panel B). 
AaPAL was detected by immunoblot using anti-AaPAL peptide antiserum. Samples for bacterial culture and enumeration were 
taken from the inserts containing serum or broth (Panel C) at the same time points as the samples for the immunoblots in Pan-
els A and B. The results show means (SD) from three independent experiments.
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serum incubation of D7SS, D7SS-p, and No bacteria was
carried out by using an antiserum raised against whole cell
antigen of A. actinomycetemcomitans serotype a (both D7SS
and D7SS-p are of serotype a). Several immunoreactive
bands of unknown identity but representing apparent
molecular weights ≈ 10–120 kDa were detected in the fil-
trates from both D7SS and D7SS-p, but not in the No bac-
teria controls (data not shown).
Extracellular release of AaPAL was independent of cell 
lysis
To exclude the possibility that the A. actinomycetemcomi-
tans cells had lysed in the inserts, the filtrates in which
AaPAL was detected were also tested by immunoblotting
using specific antibodies against a cytoplasmic marker,
cAMP receptor protein. Anti-Vibrio cholerae cAMP receptor
protein antibodies were chosen since the protein is 79%
identical and 94% similar to A. actinomycetemcomitans
cAMP receptor protein. Whole cell protein preparation of
V. cholerae (crp+) reacted at an expected 23 kDa size,
whereas A. actinomycetemcomitans whole cell protein prep-
aration showed an immunoreactive band at ≈ 27 kDa (Fig.
6). This molecular weight was higher than the weight
deduced from its amino acid sequence, 24.2 kDa (Oral-
gen; Oral Pathogen Sequence Database).
Our findings demonstrate that cAMP receptor protein
could not be detected in any of the filtrate samples
obtained from the cell-culture insert model (Fig. 6), not
even when the filtrates were concentrated with trichloro-
acetic acid precipitation (data not shown).
To show that soluble cAMP receptor protein could be
detected in filtrates from lysed bacteria, deliberately bro-
ken (See Methods) A. actinomycetemcomitans cells were
incubated in cell culture inserts containing broth for 8 h
as described above. As shown in Fig. 6, filtrates from lysed
but not from unlysed D7SS cells contained detectable
amounts of cAMP receptor protein.
AaPAL was associated with A. actinomycetemcomitans 
outer membrane vesicles
To investigate whether AaPAL could be detected in associ-
ation with the vesicles, the vesicle preparations were ana-
lyzed using immunoblotting. A weak 17-kDa signal was
detected in D7SS but not D7SS-p vesicles (Fig. 7), whereas
the vesicle preparation supernatants obtained after ultra-
centrifugation (containing soluble bacterial compo-
nents), showed a strong AaPAL signal for strain D7SS
(D7SS-p was negative) (Fig. 7).
Extracellular release of AaPAL was independent of outer 
membrane vesicles
Since AaPAL was detected in vesicle preparations from A.
actinomycetemcomitans  cultures (Fig. 7), we wanted to
exclude the possibility that vesicles were the source of
AaPAL in the filtrates. Electron microscopic examination
of the vesicle preparations of the filtrates demonstrated
large amounts of serum protein aggregates in all filtrates
(Fig. 8). However, no vesicles were found in any of the fil-
trates at any time point. Data from time point 8 h are
shown in Fig. 8. Vesicle preparations from D7SS whole
cell suspension, used as a positive control, revealed vesi-
cles of an average diameter 0.05–0.2 µm (Fig. 8).
AaPAL induced cytokines in an ex vivo model
The effect of AaPAL on the cytokine milieu in human
whole blood was profiled by using a cytokine antibody
array and a preparation of affinity purified AaPAL, con-
taining less than 5 pg LPS per µg of AaPAL [3]. Production
of interleukins IL-6 and IL-8, and a macrophage inflam-
LPS released by A. actinomycetemcomitans cells using a cell cul- ture insert model Figure 5
LPS released by A. actinomycetemcomitans cells using a cell cul-
ture insert model. Filtrates from serum incubation at 0, 2, 
and 8 h (Panel A) and broth culture at 0 and 24 h (Panel B) 
were subjected to quantification of LPS by Limulus assay. The 
results are means (SD) from two independent experiments.
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matory protein, MIP-1β, was demonstrated by enhanced
signals (Fig. 9). Based on visual analysis the effects
appeared to be concentration-dependent.
Discussion
The present study demonstrates that A. actinomycetemcom-
itans releases AaPAL, a structural OMLP, in free-soluble
form. The primary route for outer membrane components
of bacteria, such as LPS and various proteins including
porins [18,19,28,29] to the extracellular space is through
the release of outer membrane vesicles. Although not
widely studied, there are a few reports on the release of
OMPs, such as OmpA, PAL, and major lipoprotein
(Braun's lipoprotein), either in soluble form [21,25,30] or
in the form of complexes [23,31]. In those studies, how-
ever, the methods were not designed to exclude the pres-
ence of vesicles in the samples [25,31,32] or bacterial
death or lysis [21,25,30-32]. Our study made an attempt
to control those factors and showed that AaPAL is released
independent of vesicles. Release of free-soluble bacterial
components, such as shown here for a lipoprotein, would
be of biological significance, since these components can
cross anatomical barriers impermeable to whole bacteria
or even vesicles [33-35]. In addition, there is evidence to
suggest that in free form bacterial components convey
higher biological activity than when they are membrane-
bound in intact bacteria or in vesicles [26]. Regardless, the
results of the present study accentuate a less studied strat-
egy by which oral bacteria, like bacteria in other localized
infections, may express extended pathogenicity.
Our experimental model comprised a cell culture insert.
Based on the previous literature on A. actinomycetemcomi-
tans outer membrane vesicles [36], we chose a membrane
filter with a pore size (0.02 µm) that would not allow cells
or vesicles to pass through. An electron microscopic exam-
ination verified that the vesicle size for the present A.
actinomycetemcomitans strains indeed was larger than the
pores in the chosen filter. This renders unlikely the possi-
bility that vesicles would have passed through the filter,
which was further confirmed by the absence of vesicles in
the filtrates. No literature was found about release of
material from intact vesicles. Instead, vesicles are known
to be considerably stable structures [37,38] and therefore,
the possibility that lysed vesicles would have been the
source of free-soluble AaPAL may be low.
Yet another possibility was that A. actinomycetemcomitans
cells had died and lysed in the inserts, so we continuously
monitored the viability of the bacteria grown in the
inserts. The fact the total bacterial numbers increased over
time shows that viability was maintained in the experi-
ments. However, despite the increased total numbers,
lysis of dying bacteria in the growing A. actinomycetemcom-
itans population may have presented a source of AaPAL in
the filtrate. Therefore, we, like others [39,40], excluded
the possibility of bacterial lysis by confirming the absence
of a cytoplasmic marker in the same filtrate samples from
which AaPAL was found.
Thus, neither vesicles passing through the filters nor cell
death/lysis seemed to be the source of AaPAL in the filtrate
samples. Further studies are needed to clarify the mecha-
nism by which free-soluble AaPAL is released into extra-
cellular space and how the release is regulated. Currently,
it would be tempting to speculate that the mechanism
involves activation of outer membrane phospholipase A
[41-43]. By degrading phospholipids of the outer mem-
brane, phospholipase A could liberate AaPAL along with
Immunoblot analysis of the filtrates for the detection of a  cytoplasmic marker, cAMP receptor protein Figure 6
Immunoblot analysis of the filtrates for the detection of a 
cytoplasmic marker, cAMP receptor protein. The whole cell 
protein preparations of V. cholerae crp+ strain (lane 1), V. chol-
erae crp- strain (lane 2) and A. actinomycetemcomitans D7SS 
(lane 3) were used as controls in the immunoblot with anti-
bodies against V. cholerae cAMP receptor protein. Serum fil-
trates (8 h): D7SS (lane 4), D7SS-p (lane 5) and No bacteria 
control (lane 6). Broth filtrates (24 h): D7SS (lane 7), D7SS-p 
(lane 8) and No bacteria control (lane 9). Detection of cAMP 
receptor protein from precipitated filtrates of lysed (lane 10) 
and unlysed D7SS cells (lane 11) incubated in the inserts con-
taining broth for 8 h.
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Immunoblot analysis of the vesicle preparations from A. actin- omycetemcomitans strains D7SS and D7SS-p Figure 7
Immunoblot analysis of the vesicle preparations from A. actin-
omycetemcomitans strains D7SS and D7SS-p. The samples (5 
µg protein each) were subjected to immunoblot analysis 
using anti-AaPAL peptide antiserum (1:500). The chemilumi-
nescence signal was captured using a CCD camera integrated 
in ChemiDoc™ XRS gel documentation system (Bio-Rad). 
The images captured by the camera were acquired and 
imported to the attached computer using QuantityOne® 
software (Bio-Rad). Lanes: D7SS (lanes 1, 3, 5) and D7SS-p 
(lanes 2, 4, 6). WCP; whole cell protein.
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other components of the outer membrane into the extra-
cellular milieu. For other species, release of cell compo-
nents, such as proteins, LPS and phospholipids has been
reported following activation of phospholipase A, with-
out an effect on growth or cell morphology [44]. Due to
its strict regulation, phospholipase A activity does not lead
to bacterial cell lysis [41,45].
For the biological activity of the released free-soluble
AaPAL it is crucial that it retains the lipid domain, because
lipoprotein-mediated cytokine induction is solely attrib-
uted to the lipid domain [46]. Our results support the
retention of the lipid part of AaPAL, since the immunob-
lot detection from the filtrate demonstrated a band of the
same MW (≈ 17 kDa) as that of purified AaPAL (without
lipid domain, the amino acid sequence-based theoretical
MW of AaPAL is ≈ 14 kDa). Therefore, the extracellularly
released AaPAL seems to be neither proteolytically cleaved
nor missing its lipid domain. The activity of free-soluble
AaPAL may also be related to its association with other
bacterial components. Our present study did not provide
data to suggest an association but demonstrated co-release
of AaPAL with LPS and other unidentified A. actinomyce-
temcomitans components. However, an association is pos-
sible, since previous studies have shown tight association
between LPS and released E. coli PAL [8], as well as
between extracellularly released OmpA, major lipopro-
tein, PAL and LPS [23,31].
Since in this study we were unable to obtain the extracel-
lularly released AaPAL in pure form and therefore did not
know whether or not it was complexed with other bacte-
rial components, we chose to study the immunostimula-
tory effect of purified AaPAL in an ex vivo model. Our
results showed a dose-dependent enhancement in the
production of IL-6, IL-8, and MIP-1β after an 8-h stimula-
tion, using purified AaPAL. A search of the literature
revealed no previous studies of cytokine production from
whole blood by using AaPAL, or other lipoproteins or
OMPs of this species. The only study on other species also
Electron micrographs of the vesicle preparations from filtrates Figure 8
Electron micrographs of the vesicle preparations from filtrates. Filtrates from experiments studying in vitro AaPAL release into 
serum were subjected to vesicle preparation and subsequent electron microscopy. The filtrates were: A. actinomycetemcomitans 
D7SS at 8 h (Panel A), D7SS-p at 8 h (Panel B), No bacteria control at 2 h (Panel C). The vesicle preparation from A. actinomyc-
etemcomitans D7SS whole cells (positive control) shows vesicles of different sizes indicated by arrows (Panel D). Bars; 0.2 µm.
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reported an increased IL-6 production from blood after
incubation with E. coli PAL [8]. In general, IL-6 and IL-8
are among the major cytokines produced by whole blood
after stimulation with bacterial components [47-52]. IL-6
has a wide range of biological activities, among them
proinflammatory properties and a role as the main stimu-
lus for acute phase protein synthesis and release from liver
in infection [53]. One of the two chemokines induced by
AaPAL in our study, IL-8, a prototypic CXC-chemokine
and classically known as a neutrophil chemoattractant,
mediates monocyte trafficking and functions as a macro-
phage stimulator [54]. The other chemokine, MIP-1β, a
CC-subfamily chemokine, is a potent chemoattractant for
monocytes and T cells [55]. Thus, even though we cur-
rently do not know the bioactivity of released free-soluble
AaPAL, in purified form AaPAL has proinflammatory and
prochemotactic properties that can lead to stimulation
and differentiation of various cell types and further pro-
duction of cytokines.
Our consistent results from RFLP of the A. actinomycetem-
comitans pal gene and the immunoblot detection of the
gene product indicate that the gene is conserved and the
protein ubiquitously expressed in clonally diverse A. actin-
omycetemcomitans strains. This is in agreement with the
intraspecies conservation of pal  in other Pasteurellaceae
members, such as Haemophilus influenzae [56]. The
intraspecies conservation of AaPAL suggests that its bioac-
tivity is comparable among different A. actinomycetemcom-
itans strains. The fact that AaPAL was expressed in a variety
of different nutritional and atmospheric conditions may
underscore its importance for the normal function of the
bacterium. In addition, AaPAL was expressed during the
exposure to serum and culture in anaerobic atmosphere.
Cytokine induction of human whole blood by AaPAL Figure 9
Cytokine induction of human whole blood by AaPAL. A cytokine antibody array was used to detect cytokines produced by 
human whole blood after stimulation with purified AaPAL (5 and 1 µg/ml of blood) for 8 h. Storage buffer of AaPAL served as 
the negative control. Abbreviations: pos = positive, neg = negative.
1  2  3  4  5  6  7  8 
A Eotaxin IP-10 Rantes pos
B GM-CSF TNF-α Leptin pos
C IL-1α IL-3 IL-6 neg
D IL-1β IL-4 IL-8 neg
E IL-10 IL-17 MIP1β pos
F IL-12 MIP1α MIP-5 pos
1 2  3 4 5 6 7  8                     1 2  3 4 5 6 7 8                     1  2  3 4 5  6 7  8 
A
B
C
D
E
F
AaPAL 5 µg/ml                       AaPAL 1 µg/ml                            Control BMC Microbiology 2008, 8:18 http://www.biomedcentral.com/1471-2180/8/18
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Since these conditions bear resemblance to those in path-
ologically deepened periodontal pockets, the results sug-
gest that AaPAL is also expressed in vivo.
We included the pal-deficient mutant strains of A. actino-
mycetemcomitans primarily to corroborate our results from
the immunoblot and other experiments. Comparisons of
the phenotypic characteristics of the mutant and parent
may, however, provide preliminary information about
the role and function of AaPAL in A. actinomycetemcomi-
tans  cell physiology. We found that the mutants had
decreased growth rate and filamentous cell morphology,
differing partly from the pal-deficient mutant of H. ducreyi,
which showed unchanged growth rate [14]. Although
there were limitations in the present methods for estimat-
ing bacterial numbers, our results are consistent with pre-
vious reports demonstrating reduced growth rate of
bacteria with mutations in tol-pal genes [13,57,58]. More-
over, the antimicrobial susceptibility of the pal-deficient
A. actinomycetemcomitans mutant, D7SS-p, selectively
changed. The susceptibility to erythromycin, but not to
the  β-lactams, increased. Previous studies have shown
increased antibiotic susceptibility of strains with tol-pal
gene mutations [59]. Additionally, mutations in genes
encoding certain OMPs, such as ssc and envA of E. coli
(encode 36- and 34-kDa OMPs, respectively), have
resulted in hypersusceptibility to hydrophobic antibiotics,
including erythromycin [60]. Our finding that the suscep-
tibility of the pal-deficient  A. actinomycetemcomitans
mutant to the tested β-lactams did not increase may result
from the inefficiency of the β-lactam antibiotics to kill
slowly multiplying bacteria [61].
Conclusion
Our results suggest that live A. actinomycetemcomitans cells
release AaPAL in free-soluble form independent of vesi-
cles. The proinflammatory and prochemotactic properties
of AaPAL may contribute to producing a long-term
immune challenge in persistent A. actinomycetemcomitans-
associated infections. The extracellular release of PAL is
also of more general interest because bacterial lipopro-
teins are increasingly being recognized as playing an
important role in bacterial pathogenicity [7,14,62].
Methods
Bacteria and culture conditions
The test bacteria included 33 A. actinomycetemcomitans
strains of 6 serotypes [63-65] and 15 genotypes [66,67]. A.
actinomycetemcomitans strains were of oral (N = 31) and
non-oral (N = 2) origin. Unless otherwise stated, strains
were cultured on either supplemented blood agar plates
[4], tryptic soy agar plates (TSA), or broth (TSB) (supple-
mented with 0.6% yeast extract, 0.8% glucose) (Difco,
Sparks, MD, USA) and incubated in either CO2-enriched
air (5%) or anaerobic atmosphere (85% N2, 10% H2, 5%
CO2) at 37°C for 3 d. For biofilm growth [27], the bacte-
ria were cultured in TSB in a 24-well cell culture plate
(Nunc™, Nunc, Denmark) and incubated in either CO2-
enriched air or anaerobic atmosphere, as detailed above,
for 5 d. V. cholerae strains BML24/pHA 7 (crp+) and
BML24/pBR322 (crp-) (Wai, unpublished) were cultured
in Luria Bertani broth at 37°C overnight with shaking.
Production of anti-AaPAL peptide antiserum
Antiserum was raised in rabbit against two synthetic pep-
tides of AaPAL (N-terminal: 4–37 and C-terminal: 123–
136), as described earlier [3].
SDS-PAGE and immunoblot
Bacterial outer membrane fraction was extracted as previ-
ously described [4]. Bacteria suspended in PBS were used
for whole cell protein preparation. SDS-PAGE and immu-
noblot were performed as previously described [4]. For
immunoblots we used anti-AaPAL peptide antiserum [3],
an antiserum against whole cells of A. actinomycetemcomi-
tans serotype a [64], and V. cholerae cAMP receptor protein
[68]. Unless specified otherwise, the antisera were used at
final dilutions of 1:100 000, 1:1000, and 1:3000, respec-
tively. Horseradish peroxidase-conjugated anti-rabbit sec-
ondary antibodies were used at a final dilution of 1:10000
or 1:20000. Immunoreactive bands were visualized using
SuperSignal® (Pierce, Rockford, IL, USA).
pal-deficient mutant strains
D7SS-p, the pal-deficient mutant derivative of strain D7SS
(spontaneous smooth-colony variant of wild-type D7S),
was constructed by gene replacement technique as
described earlier [69]. The pal::Spe allele of D7SS-p was
transferred to the wild-type fimbriated strain D7S, using
natural transformation [70], generating D7S-p. The pres-
ence of the pal::Spe allele in D7S-p was confirmed by PCR
using the primers PAL-Sm 5'-CTTTCCCGGGACAT-
AACGG and PAL-Hd 5'-GCTGAAAGCTTATAGTG TAA-
GAG. The abolished AaPAL expression in the pal-deficient
mutants was confirmed by immunoblot using anti-AaPAL
peptide antiserum.
PCR-restriction fragment length polymorphism (PCR-
RFLP) of the A. actinomycetemcomitans pal sequence
For RFLP, PCR amplicons generated by the primers PAL-
SA 5'-GCTGGTTCTGTGGCTGTGT and PAL-MK 5'-ACT-
GCACGACGGTTTTTAGC were purified (QIAquick® Gel
Extraction Kit, Qiagen GmbH, Helden, Germany) and
digested with BspMI and DdeI (New England BioLabs,
Beverly, MA, USA), respectively, prior to analysis on agar-
ose (1.8%) gel electrophoresis.BMC Microbiology 2008, 8:18 http://www.biomedcentral.com/1471-2180/8/18
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Phenotypic characterization of mutants
Phenotypic characteristics, such as colony size and den-
sity, cell morphology, growth rate, and antibiotic suscep-
tibility were studied as follows:
Light microscopy
10-µl inocula containing 103 cells of strains D7SS, D7SS-
p, D7S, and D7S-p were cultured on supplemented blood
agar and TSA plates as described above and observed
under a stereomicroscope (Nikon SMZ800, Tokyo,
Japan). The cell morphology was evaluated using phase
contrast microscopy at × 1000 magnification (Leica
DMRBE).
Scanning electron microscopy (SEM)
The strains D7SS, D7SS-p, D7S, and D7S-p cultured on
TSA plates were fixed (2.5% glutaraldehyde in PBS; RT, 5
min) and prepared according to established methods. The
cells were dehydrated using increasing concentrations of
ethanol, and thereafter dried from liquid CO2 by the crit-
ical-point drying technique [71] using a Polaron E-3000
CPD apparatus (Polaron Equipment Ltd, Watford, UK).
The cover slips with attached bacteria were mounted on
aluminum stubs with silver dag (Agar Scientific Ltd, Stan-
sted, UK) and coated (approximately 15 nm of carbon
and gold) in an Edwards E12 Vacuum Coating Unit
(Edwards High Vacuum Ltd, Crawley, UK). Bacterial cell
morphology was examined in a Cambridge S360ixp scan-
ning electron microscope run with a LaB6 electron emittor
(Leica Cambridge Ltd, Cambridge, UK) and the micro-
graphs were recorded from randomly selected areas with
standardized magnifications.
Growth rate
For determining the growth rates for the strains D7SS and
D7SS-p, log-phase cultures were used to inoculate TSB.
The growth was measured as turbidity at OD600.
Antibiotic susceptibility
The D7SS and D7SS-p strains were grown in lawn cultures
(1 × 108 CFU/plate) on TSA plates on which discs of eryth-
romycin (15 µg/disc), cefotaxime (30 µg/disc), and peni-
cillin (10 U/disc) (BD Biosciences, San Jose, CA, USA)
were placed. The plates were incubated at 37°C in CO2-
enriched air for 3 d. Inhibition zones were measured in
millimeters.
Isolation of outer membrane vesicles
Outer membrane vesicles were isolated as described previ-
ously [40] with some modifications. A. actinomycetemcom-
itans  strains D7SS and D7SS-p were cultured on
supplemented blood agar plates for 3 days as described
above. Bacteria were harvested and suspended into sterile
PBS and centrifuged at 5000 × g (10 min, RT) to pellet the
bacteria. The supernatant was filtered (0.22 µm; Milli-
pore, Billerica, MA, USA) to remove any remaining intact
bacterial cells. The filtrate was ultracentrifuged at 125000
× g (3 h, 4°C) using a 70 Ti rotor (Beckman Instruments
Inc. Palo Alto, CA, USA). The obtained pellet was lyophi-
lized and suspended in sterile PBS. The outer membrane
vesicle preparations were examined by electron micros-
copy as described earlier [40]. Briefly, the vesicle samples
were stained with 0.5% uranyl acetate and examined by a
JEM 2000 ET electron micoscope (JEDL, Akishima, Tokyo,
Japan) at 100 KV.
Cell culture insert model for studying extracellular release 
of AaPAL in vitro
Cell culture insert experiments were carried out using
exposure to serum (2 and 8 h) and culture in broth (24 h)
as follows: A. actinomycetemcomitans cells (1 × 109 CFU/
ml) were suspended in heat inactivated 50% fetal calf
serum (FCS) (Invitrogen Gibco, Carlsbad, CA, USA) in
PBS. The cell suspension was transferred into inserts
(membrane pore size 0.02 µm), which were placed in cell
culture wells (Nunc) containing FCS. The procedure for
culturing in broth was similar to that for FCS, except that
the wells contained TSB and the bacterial cells were sus-
pended in TSB to a concentration of 1 × 108 CFU/ml.
Inserts containing serum or broth without bacteria served
as negative controls.
For detection of released AaPAL, following incubation at
37°C in CO2-enriched air, 100 µl samples, referred to as
"filtrates" henceforth, were taken from serum (at 0, 2, and
8 h) and broth (at 0 and 24 h) from the wells outside the
inserts. Samples from serum and broth filtrates, contain-
ing 10 and 30 µg protein, respectively, were subjected to
immunoblot analysis. The amount of AaPAL released into
serum filtrate was quantified by densitometry (Quantity
One® software, Bio-Rad, Hercules, CA, USA) using puri-
fied AaPAL (2, 4, 6, and 8 ng) as a reference. As the inten-
sities of AaPAL bands were very similar in all three
independent experiments, data from only one experiment
was chosen for densitometric quantification.
To monitor the viability of A. actinomycetemcomitans cells
in serum and broth during incubation, 10-µl samples of
the bacterial suspensions were taken from the inserts at
the same time points as the samples were taken from the
filtrates for immunoblot. Since bacterial cells might have
sedimented to the bottom during incubation, the bacte-
rial suspensions inside the inserts were pipetted in and
out repeatedly 4–5 times to make the suspension homo-
geneous before taking out the samples for culture and via-
ble counts. Appropriate serial dilutions of the samples
were plated on supplemented blood agar plates and incu-
bated at 37°C in CO2-enriched air for 3 d. To exclude bac-
terial contamination of the serum or broth filtrates, 10-µl
samples were also taken and cultured on supplementedBMC Microbiology 2008, 8:18 http://www.biomedcentral.com/1471-2180/8/18
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blood agar plates. Limulus assay (Cape Cod, E. Falmouth,
MA, USA) was used for the detection of LPS in the filtrates.
To ensure that the integrity of the insert membrane
remained intact (i.e., no leakage of bacterial cells) and
that AaPAL found in the filtrate was not due to cell lysis in
the insert, immunoblot was used to analyze the presence
of a cytoplasmic marker protein, cAMP receptor protein,
in the filtrates, as described above for the detection of
AaPAL. For concentration, the filtrates were precipitated
using ice-cold trichloroacetic acid (final concentration
10%).
To deliberately cause release of cytoplasmic proteins, A.
actinomycetemcomitans D7SS cells (2 × 109 cells/ml) were
lysed using Lysing matrix E provided in the FastDNA ®
SPIN Kit for Soil (BIO 101, Q-Biogen, Montreal, Canada)
with Mini-BeadBeater-8 (BioSpec Products Inc., Bartles-
ville, OK, USA) at highest speed for 3 min. The lysed cells
were incubated in broth in the cell culture insert as
described above. Unlysed cells were incubated similarly as
a negative control. After 8 h incubation, filtrates collected
from the wells were TCA-precipitated and the cAMP recep-
tor protein was detected by immunoblotting as above.
To investigate whether outer membrane vesicles passed
through the insert membrane filters in our experimental
setup, serum filtrates were ultracentrifuged using the same
procedure for sample preparation and electron micro-
scopic examination as described above for the isolation of
outer membrane vesicles.
Cytokine induction from human whole blood by AaPAL
AaPAL was purified by affinity chromatography as
described previously [3]. Each microgram of purified
AaPAL had LPS contamination of less than 5 pg, an
amount which was shown not to contribute to AaPAL-
induced cytokine production [72]. AaPAL TranSignal
human cytokine antibody arrays (Panomics, Redwood
City, CA, USA) were used to profile cytokines produced by
human whole blood. Blood sample from a healthy indi-
vidual was drawn via venipuncture into heparin-contain-
ing tubes (BD Biosciences). Blood was immediately
stimulated with AaPAL (final concentration 1 and 5 µg/ml
blood; 37°C, 5% CO2, 8 h), followed by centrifugation
(5000 × g, 5 min) and cytokine analysis of the superna-
tants (5-fold dilutions) as instructed by the array manu-
facturer. Blood stimulated with AaPAL storage buffer
served as a reference. Aliquots of blood were taken at 0 h
and 8 h and plated on supplemented blood agar plates for
bacterial contamination check. The experiment was
repeated once.
Statistical analysis
Unless otherwise indicated all experiments were repeated
thrice. Mann-Whitney U test was used to determine the
significance of the differences between the parental strain
and the isogenic mutant in antibiotic susceptibilities and
in the LPS amounts released into serum or broth. A P-
value of less than 0.05 was regarded as statistically signif-
icant.
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